A Multi-Center Real-World Study of Clinicopathologic Characteristics and Efficacy of the Malignant Mesothelioma in Chinese Population

被引：0

作者：

Sun, Chenrui ^{[1
]}

Yang, Xue ^{[2
]}

Chen, Lan ^{[3
,4
]}

Bie, Zhixin ^{[5
]}

Kang, Runting ^{[1
]}

Ai, Bin ^{[6
]}

Ma, Junling ^{[6
]}

Zheng, Zitong ^{[7
]}

Liu, Haolan ^{[7
]}

Liu, Juanjuan ^{[1
]}

Zhong, Jia ^{[8
]}

Yu, Jiangyong ^{[1
]}

机构：

[1] Chinese Acad Med Sci, Beijing Hosp, Ctr Biotherapy, Natl Ctr Gerontol,Inst Geriatr Med, Beijing, Peoples R China

[2] Peking Univ Canc Hosp & Inst, Dept Thorac Oncol 1, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China

[3] Chinese Acad Med Sci, Beijing Hosp, Natl Ctr Gerontol, Dept Pathol, Beijing, Peoples R China

[4] Chinese Acad Med Sci, Inst Geriatr Med, Beijing, Peoples R China

[5] Chinese Acad Med Sci, Beijing Hosp, Minimally Invas Tumor Therapies Ctr, Natl Ctr Gerontol Inst Geriatr Med, Beijing, Peoples R China

[6] Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Natl Ctr Gerontol,Dept Oncol, Beijing, Peoples R China

[7] Binzhou Med Univ Hosp, Dept Oncol, Binzhou, Peoples R China

[8] Chinese Acad Med Sci Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,State Key Lab Mol Oncol,CA, Beijing, Peoples R China

来源：

THORACIC CANCER | 2025年 / 16卷 / 03期

关键词：

clinical characteristic; efficacy; epidemiology; malignant mesothelioma; survival analysis; THORACIC ONCOLOGY PLATFORM; PLEURAL-MESOTHELIOMA; PHASE-III; CISPLATIN; EPIDEMIOLOGY; MUTATIONS; CANCER; BAP1; IMMUNOHISTOCHEMISTRY; RECURRENCE;

D O I：

10.1111/1759-7714.15533

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ObjectiveMalignant mesothelioma (MM) is a rare malignant tumor. To explore the clinicopathological characteristics and efficacy of Chinese population with MM in the real-world.MethodsTwo hundred and forty-eight patients diagnosed with MM between September 2007 and August 2024 from three large medical centers (Beijing Hospital, Peking University Cancer Hospital, and Chinese Academy of Medical Sciences Cancer Hospital) were retrospectively analyzed. Kaplan-Meier and Cox regression were performed. Breast cancer gene 1-associated protein 1 (BAP1) status was evaluated.ResultsChinese population with MM had a lower diagnostic age, higher proportion of youth and female, more advanced stage and lower expression of characteristic markers. The median progression-free survival (mPFS) and median overall survival (mOS) were 8.90 and 25.60 months for the first-line treatment, and 3.28 and 19.50 months for the second-line. The first-line immunotherapy provided a relatively higher objective response rate (33.3% vs. 20.5%, p = 0.402) and a trend to prolong mPFS (12.10 vs. 9.20 months, p = 0.345) and mOS (NA vs. 23.90, p = 0.185) compared with chemotherapy. Bevacizumab combined with chemotherapy relatively prolonged mPFS (10.47 vs. 7.93 months, p = 0.074) and mOS (31.30 vs. 23.20 months, p = 0.673) than chemotherapy alone. Carboplatin relatively improved mPFS than cisplatin (10.87 vs. 8.87 months, p = 0.185). Age and histologic type were predictors for PFS, and gender, histologic subtype, and CK5/6 were prognosis factors for OS. Briefly, 17.78% patients existed BAP1 deletions and correlated with OS benefit.ConclusionChinese population with MM present unique clinicopathologic characteristics and could benefit from the first-line immunotherapy and bevacizumab combined with chemotherapy. Gender, histologic subtype, and CK5/6 are prognosis factors for OS. BAP1 deletions correlate with OS benefit.

引用

页数：11

共 45 条

[1] Marinaccio A., Marzio D.D., Mensi C., Et al., Incidence of Mesothelioma in Young People and Causal Exposure to Asbestos in the Italian National Mesothelioma Registry (ReNaM), Occupational and Environmental Medicine, 80, 11, pp. 603-609, (2023)
[2] Wang J., Huang X., Ma R., Et al., The Incidence of Malignancies in Asbestosis With Chrysotile Exposure: A Large Chinese Prospective Cohort Study, Frontiers in Oncology, 13, (2023)
[3] Zhao J., Zuo T., Zheng R., Et al., Epidemiology and Trend Analysis on Malignant Mesothelioma in China, Chinese Journal of Cancer Research, 29, 4, pp. 361-368, (2017)
[4] Bianchi C., Bianchi T., Global Mesothelioma Epidemic: Trend and Features, Indian Journal Of Occupational And Environmental Medicine, 18, 2, pp. 82-88, (2014)
[5] Mao W., Zhang X., Guo Z., Et al., Association of Asbestos Exposure With Malignant Mesothelioma Incidence in Eastern China, JAMA Oncology, 3, 4, pp. 562-564, (2017)
[6] Guo Z., Carbone M., Zhang X., Et al., Improving the Accuracy of Mesothelioma Diagnosis in China, Journal of Thoracic Oncology, 12, 4, pp. 714-723, (2017)
[7] Tsao A.S., Pass H.I., Rimner A., Mansfield A.S., New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options, Journal of Clinical Oncology, 40, 6, pp. 681-692, (2022)
[8] Hassan R., Morrow B., Thomas A., Et al., Inherited Predisposition to Malignant Mesothelioma and Overall Survival Following Platinum Chemotherapy, Proceedings of the National Academy of Sciences of the United States of America, 116, 18, pp. 9008-9013, (2019)
[9] Peters S., Scherpereel A., Cornelissen R., Et al., First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Patients With Unresectable Malignant Pleural Mesothelioma: 3-Year Outcomes From CheckMate 743, Annals of Oncology, 33, 5, pp. 488-499, (2022)
[10] Kerrigan K., Jo Y., Chipman J., Et al., A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern, JTO Clinical and Research Reports, 3, 3, (2022)

← 1 2 3 4 5 →